浙江永强(002489) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥2,736,823,737.52, representing a 35.36% increase compared to ¥2,021,856,373.98 in the same period last year[9]. - Net profit attributable to shareholders was ¥234,770,779.19, a decrease of 28.26% from ¥327,244,617.18 year-on-year[9]. - The net profit after deducting non-recurring gains and losses was ¥239,903,966.74, down 17.87% from ¥292,110,412.19 in the previous year[9]. - Basic earnings per share were ¥0.11, down 26.67% from ¥0.15 in the previous year[9]. - The company reported a profit of 23,053,198.51 CNY from securities trading activities in the current period[30]. - The company's net profit for the first half of 2021 is expected to show significant changes compared to the same period last year[41]. - The company reported a total profit of ¥183,584,735.55, compared to ¥304,947,440.98 in the previous period, indicating a decline[77]. Cash Flow - The net cash flow from operating activities was ¥359,075,131.56, a decline of 35.41% compared to ¥555,950,700.27 in the same period last year[9]. - The company reported a 35.41% decline in net cash flow from operating activities to ¥359,075,131.56 due to increased payments for goods and services[25]. - Operating cash flow for the period was CNY 359,075,131.56, a decrease of 35.4% compared to CNY 555,950,700.27 in the previous period[81]. - Cash inflow from financing activities totaled CNY 220,979,600.00, down 8.4% from CNY 241,441,533.33 year-over-year[85]. - The cash and cash equivalents at the end of the period amounted to CNY 961,008,763.69, down from CNY 1,179,240,668.06 in the previous period[85]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,724,967,508.30, an increase of 5.76% from ¥7,304,118,364.80 at the end of the previous year[9]. - Total liabilities increased to approximately 3.72 billion yuan from 3.43 billion yuan, an increase of about 8.5%[56]. - The company's total liabilities increased, with accounts payable rising by 45.99% to ¥1,567,570,000.00 due to increased procurement using bank acceptance bills[22]. - Total liabilities increased to CNY 4,076,444,401.13 from CNY 3,480,143,342.53, which is an increase of approximately 17.1%[63]. - The total assets as of January 1, 2021, amounted to CNY 7,313,666,218.72, reflecting an adjustment of CNY 9,547,853.92 from the previous year[94]. Shareholder Information - Net assets attributable to shareholders were ¥3,936,571,452.40, up 3.39% from ¥3,807,645,502.33 at the end of the previous year[9]. - The total number of ordinary shareholders at the end of the reporting period was 101,509[12]. - The total equity attributable to shareholders was CNY 3,807,645,502.33, remaining unchanged from the previous year[97]. Inventory and Accounts Receivable - Accounts receivable increased by 82.57% to ¥2,347,864,382.79 due to concentrated shipments during the sales peak[22]. - Inventory decreased by 41.92% to ¥928,509,922.00 as a result of reduced stock reserves following sales shipments[22]. - Accounts receivable rose significantly to CNY 2,400,164,739.59 from CNY 1,340,813,032.81, marking an increase of approximately 78.9%[57]. - The company’s inventory decreased to CNY 513,792,045.81 from CNY 1,060,153,581.23, indicating a reduction of about 51.6%[57]. Investment Activities - The company reported a decrease in investment income, with losses of -¥805,166.53 compared to -¥270,214.39 in the previous period[74]. - The total initial investment in securities amounted to 486,789,275.50 CNY, with a fair value change of 543,802,519.79 CNY during the reporting period[30]. - The company holds a total of 8,694.46 million CNY in derivative investments, primarily in forward foreign exchange contracts[34]. - The company has implemented risk control measures for derivative investments, including internal control standards established in January 2010[36]. Research and Development - Research and development expenses increased to CNY 39,954,752.49 from CNY 31,776,045.64, representing a growth of approximately 25.7%[66]. - Research and development expenses increased to ¥34,197,532.20 from ¥27,293,615.22, reflecting a focus on innovation[74].